NCT05268783 Patient-reported Outcomes in Neuroendocrine Neoplasms: a Prospective Quality of Life and Quality of Care Study Within NETwerk
| NCT ID | NCT05268783 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Antwerp |
| Condition | Quality of Life |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2018-11-05 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2018-11-05 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neuroendocrine tumors (NET) are rare tumors that require specific diagnosis and treatment. Therefore, this poses a challenge for clinical practice. Diagnosis and treatment can be optimized when physician specialists and other healthcare providers, across various hospitals, join forces to provide patients the best care. Based on this idea, a hospital network called NETwerk was set up. The following hospitals are part of this network: University Hospital Antwerp, VITAZ, AZ Monica, AZ Voorkempen, AZ Klina, Gasthuiszusters Antwerpen, Ziekenhuis Netwerk Antwerpen and AZ Rivierenland. In this NETwerk, patients with a neuroendocrine tumor or patients suspected with a neuroendocrine tumor are discussed with the specialists and treated.The aim of this study is to map the quality of life of NET patients within NETwerk in order to optimize the quality of care. Throughout the diagnosis, the treatment process and the follow-up, the patient will be asked to fill out three questionnaires (QLQ-C30, QLQ-GI.NET21 and a satisfaction survey). These questionnaires will be filled out every six months at home. Patients will be asked to complete these questionnaires over a period of five years.
Eligibility Criteria
Inclusion Criteria: * NEN patient * 18 years or older * Patient should appear in Oncobase Exclusion Criteria: * Patients who do not have an email address
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05268783 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Quality of Life. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05268783 currently recruiting?
Yes, NCT05268783 is actively recruiting participants. Contact the research team at timon.vandamme@uza.be for enrollment information.
Where is the NCT05268783 trial being conducted?
This trial is being conducted at Brasschaat, Belgium, Deurne, Belgium, Edegem, Belgium, Rumst, Belgium and 3 additional locations.
Who is sponsoring the NCT05268783 clinical trial?
NCT05268783 is sponsored by University Hospital, Antwerp. The trial plans to enroll 1,000 participants.